Clinical Trial

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Study acronym: SANTANA-225

Terminated Phase 1/2

View on ClinicalTrials.gov →

Why the trial stopped

Study terminated due to strategic business decisions.

Summary

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2025-04-15; most recent amendment 2026-02-03.

Status change: Recruiting → Terminated 2026-02-03

Trial Details

NCT Number	NCT06939036
Lead Sponsor	Ariceum Therapeutics GmbH
Conditions	Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Enrollment	2 participants
Start Date	2025-07-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-05